» Articles » PMID: 10559315

Overexpression of Cyclin A Inhibits Augmentation of Recombinant Adeno-associated Virus Transduction by the Adenovirus E4orf6 Protein

Overview
Journal J Virol
Date 1999 Nov 13
PMID 10559315
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

The 34-kDa product of adenovirus E4 region open reading frame 6 (E4orf6) dramatically enhances transduction by recombinant adeno-associated virus vectors (rAAV). This is achieved by promoting the conversion of incoming single-stranded viral genomes into transcriptionally competent duplex molecules. The molecular mechanism for enhancing second-strand synthesis is not fully understood. In this study, we analyzed the cellular consequences of E4orf6 expression and the requirements for efficient rAAV transduction mediated by E4orf6. Expression of E4orf6 in 293 cells led to an inhibition of cell cycle progression and an accumulation of cells in S phase. This was preceded by specific degradation of cyclin A and p53, while the levels of other proteins involved in cell cycle control remained unchanged. In addition, the kinase activity of cdc2 was inhibited. We further showed that p53 expression is not necessary or inhibitory for augmentation of rAAV transduction by E4orf6. However, overexpression of cyclin A inhibited E4orf6-mediated enhancement of rAAV transduction. A cyclin A mutant incapable of recruiting protein substrates for cdk2 was unable to inhibit E4orf6-mediated augmentation. In addition, we created an E4orf6 mutant that is selectively defective in rAAV augmentation of transduction. Based on these findings, we suggest that cyclin A degradation represents a viral mechanism to disrupt cell cycle progression, resulting in enhanced viral transduction. Understanding the cellular pathways used during transduction will increase the utility of rAAV vectors in a wide range of gene therapy applications.

Citing Articles

Adenovirus-mediated ubiquitination alters protein-RNA binding and aids viral RNA processing.

Herrmann C, Dybas J, Liddle J, Price A, Hayer K, Lauman R Nat Microbiol. 2020; 5(10):1217-1231.

PMID: 32661314 PMC: 7529849. DOI: 10.1038/s41564-020-0750-9.


Herpes simplex virus type 1/adeno-associated virus hybrid vectors.

de Oliveira A, Fraefel C Open Virol J. 2010; 4:109-22.

PMID: 20811580 PMC: 2930156. DOI: 10.2174/1874357901004030109.


Adeno-associated virus and adenovirus coinfection induces a cellular DNA damage and repair response via redundant phosphatidylinositol 3-like kinase pathways.

Collaco R, Bevington J, Bhrigu V, Kalman-Maltese V, Trempe J Virology. 2009; 392(1):24-33.

PMID: 19628243 PMC: 2742906. DOI: 10.1016/j.virol.2009.06.005.


Adeno-associated virus infection of murine fibroblasts with help provided by mouse adenovirus.

Bhrigu V, Trempe J Virology. 2009; 390(1):22-30.

PMID: 19464040 PMC: 2706943. DOI: 10.1016/j.virol.2009.04.020.


Identification of cellular proteins that interact with the adeno-associated virus rep protein.

Nash K, Chen W, Salganik M, Muzyczka N J Virol. 2008; 83(1):454-69.

PMID: 18971280 PMC: 2612328. DOI: 10.1128/JVI.01939-08.


References
1.
Moore M, Horikoshi N, Shenk T . Oncogenic potential of the adenovirus E4orf6 protein. Proc Natl Acad Sci U S A. 1996; 93(21):11295-301. PMC: 38051. DOI: 10.1073/pnas.93.21.11295. View

2.
Elledge S . Cell cycle checkpoints: preventing an identity crisis. Science. 1996; 274(5293):1664-72. DOI: 10.1126/science.274.5293.1664. View

3.
Lew D, Kornbluth S . Regulatory roles of cyclin dependent kinase phosphorylation in cell cycle control. Curr Opin Cell Biol. 1996; 8(6):795-804. DOI: 10.1016/s0955-0674(96)80080-9. View

4.
Adams P, Sellers W, Sharma S, Wu A, Nalin C, Kaelin Jr W . Identification of a cyclin-cdk2 recognition motif present in substrates and p21-like cyclin-dependent kinase inhibitors. Mol Cell Biol. 1996; 16(12):6623-33. PMC: 231664. DOI: 10.1128/MCB.16.12.6623. View

5.
Gao G, Yang Y, Wilson J . Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy. J Virol. 1996; 70(12):8934-43. PMC: 190991. DOI: 10.1128/JVI.70.12.8934-8943.1996. View